{"meta":{"id":"https:\/\/api.iclient.ifeng.com\/ipadtestdoc?aid=ucms_7wol04eq18l","type":"doc","o":"1","documentId":"ucms_7wol04eq18l"},"body":{"newStatus":"1","documentId":"ucms_7wol04eq18l","staticId":"ucms_7wol04eq18l","title":"博雅辑因和艺妙神州宣布将共同研发用于治疗癌症的异体CAR-T疗法","shareTitle":"博雅辑因和艺妙神州宣布将共同研发用于治疗癌症的异体CAR-T疗法","thumbnail_doc":"","thumbnail":"","source":"36氪","author":"","editorcode":"weMedia","editTime":"2020-05-27 16:48:52","updateTime":"2020\/05\/27 16:48:52","wapurl":"http:\/\/\/\/feng.ifeng.com\/c\/7wol04eq18l","introduction":"","wwwurl":"http:\/\/\/\/feng.ifeng.com\/c\/7wol04eq18l","commentsUrl":"ucms_7wol04eq18l","commentCount":0,"text":"
36氪获悉,博雅辑因与艺妙神州宣布将合作研发用于治疗癌症的异体CAR-T疗法。博雅辑因是一家以基因组编辑技术为基础,针对多种疾病加速药物研究并开发创新疗法的生物医药企业。艺妙神州是一家专注于基因细胞药物技术的创新型生物技术公司。双方将共同研发潜在的同类最佳异体CAR-T疗法。合作细节条款未披露。<\/p>","img":[],"summary":"36氪获悉,博雅辑因与艺妙神州宣布将合作研发用于治疗癌症的异体CAR-T疗法。博雅辑因是一家以基因组编辑技术为基础,针对多种疾病加速药物研究并开发创新疗法的生物","sharesummary":"36氪获悉,博雅辑因与艺妙神州宣布将合作研发用于治疗癌症的异体CAR-T疗法。博雅辑因是一家以基因组编辑技术为基础,针对多种疾病加速药物研究并开发创新疗法的生物","commentType":"0","wemediaEAccountId":"1529993","showclient":"0","shareurl":"https:\/\/ishare.ifeng.com\/c\/s\/v002EMTX--Jvg51xqrwAwb75kkGb4eDV9tptt-_gf-_PT9sy5Q__","praise":"0","like_num":"0"}}